|
Accueil > Actualité
Medincell: a milestone payment from Teva
(CercleFinance.com) - Medincell announces that it will receive a milestone payment of five million dollars from Teva Pharmaceuticals, in accordance with their agreement for the clinical development of Olanzapine LAI (extended-release injection) in schizophrenia.
The biopharmaceutical company explains that the pivotal Phase 3 SOLARIS clinical trial has indeed been completed, with the last patient of the 48-week open-label safety period having completed his final visit, thus activating this milestone to its benefit. Teva is now preparing the marketing application and launch of Olanzapine LAI, with publication of all long-term safety data scheduled for the second quarter and filing in the second half of 2025. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
29/05/2025 18:20
DanoneShane Grant sur le départ 29/05/2025 17:30 Teslatitre en hausse, un broker confirme son conseil 29/05/2025 16:52 Alstoméquipe l'aéroport de Denver avec 19 navettes 29/05/2025 16:35 United Airlinespartenariat stratégique avec JetBlue 29/05/2025 16:22 JPMorganun banquier de HSBC recruté dans les M&A 29/05/2025 15:25 Baker Hughescommande de 16 turbines à gaz aux Etats-Unis Tous les articles sociétés |
